Evommune, Inc. (EVMN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in Capital, Common StockUSD $552.59M; Retained Earnings (Accumulated Deficit)USD $-275.01M; Stockholders' Equity Attributable to ParentUSD $277.59M.
- 2026-03-31: Common Stock, Value, IssuedUSD $4.00K; Additional Paid in Capital, Common StockUSD $547.31M; Retained Earnings (Accumulated Deficit)USD $-242.76M; Stockholders' Equity Attributable to ParentUSD $304.56M.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $426.65M; Retained Earnings (Accumulated Deficit)USD $-221.09M; Stockholders' Equity Attributable to ParentUSD $205.57M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $9.68M; Retained Earnings (Accumulated Deficit)USD $-192.82M; Stockholders' Equity Attributable to ParentUSD $-183.14M.
Evommune, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|
| 2026-06-30 | $4.00K | $552.59M | $-275.01M | $277.59M | 3 month · $4.60M 6 month · $8.05M |
| 2026-03-31 | $4.00K | $547.31M | $-242.76M | $304.56M | 3 month · $3.45M |
| 2025-12-31 | $3.00K | $426.65M | $-221.09M | $205.57M | 12 month · $5.86M |
| 2025-09-30 | $0.00 | $9.68M | $-192.82M | $-183.14M | 3 month · $561.00K 9 month · $1.66M |
| 2025-06-30 | (m) | (m) | (m) | $-171.23M | 3 month · $557.00K 6 month · $1.10M |
| 2025-03-31 | (m) | (m) | (m) | $-158.24M | 3 month · $544.00K |
| 2024-12-31 | $0.00 | $7.98M | $-152.22M | $-144.24M | 12 month · $1.72M |
| 2024-09-30 | (m) | (m) | (m) | $-122.53M | 3 month · $401.00K 9 month · $1.23M |
| 2024-06-30 | (m) | (m) | (m) | $-107.03M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $-77.71M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |